Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C

被引：2

作者：

Assmar, Mehdi ^{[1
]}

Yeganeh, Sara ^{[1
]}

Mansourghanaei, Fariborz ^{[2
]}

Amirmozafari, Nour ^{[3
]}

机构：

[1] Islamic Azad Univ, Dept Microbiol, Lahijan, Iran

[2] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran

[3] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran

来源：

IRANIAN JOURNAL OF PUBLIC HEALTH | 2016年 / 45卷 / 12期

关键词：

Tumor markers; Hepatitis B; Hepatitis C; ELISA; CLINICAL-IMPLICATIONS; ALPHA-FETOPROTEIN; LIVER-DISEASE; SERUM; CANCER; EPIDEMIOLOGY; PREVALENCE; INFECTION; ANTIGEN;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: This study aimed to determine the role of tumor markers AFP, CA15-3, CA125, CA19-9 and CEA in patients with hepatitis B and C. Methods: This descriptive cross-sectional study was performed from Oct 2012 to Oct 2014. Serum samples of 129 patients with hepatitis B and C referred to Guilan Liver and Digestive Disease Research Center in Rasht, Iran were collected and checked for the existence of the listed tumor markers by ELISA. Results: No increase in serum levels of tumor marker CA19-9, CEA and CA15-3 were seen in patients with hepatitis (P>0.05). In patients with hepatitis B, increase in CA125 were observed (P=0.03). In hepatitis C patients, there was an increase in AFP levels (P=0.03). Conclusion: The levels of AFP and CA125 markers were high in hepatitis C and hepatitis B, respectively. However, the increased levels were not seen is malignancy. Due to the small sample size, further study is necessary to find the reasons of the increase.

引用

页码：1645 / 1651

页数：7

共 29 条

[1]

Al-boki EL-H, 2011, EGYPTION LIVER J, V1, P33

[2]

Alavian SM, 2007, J GASTROINTEST LIVER, V16, P403

[3]

Bertino G, 2007, Minerva Gastroenterol Dietol, V53, P305

[4] Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23 [J].